Drug Price Trends for LATUDA

Average Pharmacy Cost for LATUDA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
LATUDA 40 MG TABLET	63402-0304-30	46.71830	EACH	2026-01-01
LATUDA 60 MG TABLET	63402-0306-30	46.78946	EACH	2026-01-01
LATUDA 120 MG TABLET	63402-0312-30	69.62079	EACH	2026-01-01
LATUDA 20 MG TABLET	63402-0302-30	46.68859	EACH	2026-01-01
LATUDA 80 MG TABLET	63402-0308-30	46.65796	EACH	2026-01-01

Latuda (Lurasidone) Market Analysis and Price Projections

Last updated: February 19, 2026

Latuda (lurasidone HCl) is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. The market for Latuda is influenced by its patent exclusivity, the emergence of generic alternatives, and the evolving landscape of mental health treatment.

What is the Current Market Size and Growth Trajectory for Latuda?

The global market for lurasidone hydrochloride has experienced significant growth, driven by its efficacy in treating schizophrenia and bipolar depression. In 2023, the market size for lurasidone was estimated to be approximately USD 3.4 billion. Projections indicate continued expansion, with an anticipated Compound Annual Growth Rate (CAGR) of 5.8% from 2023 to 2030. This growth is attributed to an increasing prevalence of mental health disorders, rising healthcare expenditure, and wider accessibility of treatment options.

Key market drivers include:

• Increasing Prevalence of Schizophrenia and Bipolar Disorder: The World Health Organization (WHO) estimates that over 24 million people suffer from schizophrenia globally. Bipolar disorder affects an estimated 40 million people worldwide [1]. These rising figures directly correlate with the demand for effective treatments like Latuda.
• Market Penetration and Prescribing Trends: Latuda has established a strong market presence since its initial approval. Prescribing patterns indicate its continued use in treatment algorithms for these conditions.
• Geographic Expansion: The drug's availability and adoption vary across regions, with North America and Europe representing significant markets, and emerging economies showing increasing potential.

What is the Patent Landscape for Latuda and When Does Generic Entry Occur?

The patent protection for Latuda has been a critical factor in its market performance. The primary U.S. patents for lurasidone hydrochloride, including composition of matter and method of use patents, have either expired or are nearing expiration, allowing for generic competition.

• Key Patent Expirations:

  • The U.S. Patent No. 5,939,403 (composition of matter) expired on July 31, 2019.
  • U.S. Patent No. 7,199,119 (method of use for bipolar depression) expired on July 13, 2023 [2].
  • Other method of use patents related to schizophrenia treatment have also expired or are subject to ongoing litigation and potential challenges.

• Generic Entry: The expiration of key patents has paved the way for the introduction of generic lurasidone hydrochloride products. Generic versions began entering the U.S. market in early 2023, following the expiration of the 7,199,119 patent and the resolution of certain patent disputes.

The introduction of generics significantly impacts the market dynamics by increasing competition and driving down prices.

How Will Generic Competition Affect Latuda's Pricing and Market Share?

The advent of generic lurasidone hydrochloride is expected to lead to a substantial decline in the price of the drug and a corresponding reduction in the market share held by the originator brand, manufactured by Sumitomo Pharma.

• Price Erosion: Generic drugs typically enter the market at significantly lower prices than their branded counterparts. Historically, prices for generic antipsychotics can fall by 50% to 85% within the first year of market entry, depending on the number of generic manufacturers and the formulary status. For Latuda, this price erosion will be a direct consequence of increased competition.
• Market Share Shift: The originator brand's market share will diminish as healthcare providers and payers transition to more cost-effective generic alternatives. While the originator brand may retain a portion of the market due to physician preference or specific contractual agreements, the majority of the volume is expected to shift to generics.
• Impact on Sales: Sumitomo Pharma's revenue from Latuda is projected to decline sharply following widespread generic entry. The company had already experienced sales declines in anticipation of this event. For instance, Latuda's net sales in the U.S. for the fiscal year ended March 31, 2023, were JPY 145.5 billion, a decrease from JPY 180.4 billion in the previous fiscal year, reflecting pre-generic market pressures [3].

What are the Key Competitors and Alternative Treatments for Latuda?

The competitive landscape for Latuda includes both other atypical antipsychotics and newer treatment modalities. With the introduction of generic lurasidone, direct competition from other generic lurasidone products will be the most significant factor.

• Generic Lurasidone Products: Multiple pharmaceutical companies are poised to manufacture and market generic versions of lurasidone HCl. This will lead to a fragmented market with several suppliers.

• Other Atypical Antipsychotics (Branded and Generic):

  • Risperidone (Risperdal): A long-standing atypical antipsychotic with established efficacy.
  • Quetiapine (Seroquel): Widely used for schizophrenia and bipolar disorder, with both immediate and extended-release formulations.
  • Olanzapine (Zyprexa): Another established option, available in various formulations including long-acting injectables.
  • Aripiprazole (Abilify): Known for its broad efficacy across different psychiatric conditions.
  • Ziprasidone (Geodon): Offers a different side-effect profile compared to some other agents.
  • Paliperidone (Invega): Available in extended-release oral formulations and long-acting injectables.
  • Cariprazine (Vraylar): Approved for schizophrenia, bipolar mania, and depressive episodes associated with bipolar I disorder. It is considered a more recent entrant and a significant competitor to established agents.
  • Brexpiprazole (Rexulti): Also approved for schizophrenia and adjunctive treatment for major depressive disorder.

• Emerging Treatments: Research and development in mental health continue to explore novel therapeutic approaches, including targeted biologics and digital therapeutics, which could influence long-term treatment paradigms.

The choice of treatment often depends on individual patient response, side effect profiles, co-morbidities, and cost.

What are the Projected Price Ranges for Generic Lurasidone?

Following patent expiry and the entry of multiple generic manufacturers, the price of lurasidone hydrochloride is expected to decrease significantly. While precise pricing depends on market dynamics, formulary agreements, and competition, historical trends provide an indication.

• Estimated Price Reduction: Based on the typical price erosion observed for generic antipsychotics, the Average Wholesale Price (AWP) for generic lurasidone is projected to be 70-85% lower than the branded Latuda.
• Projected Price Range: For a typical monthly prescription (e.g., 60mg daily dose), the out-of-pocket cost or payer reimbursement for generic lurasidone could range from USD 50 to USD 150, compared to branded Latuda which could cost USD 400-600 or more pre-generics, depending on insurance and pharmacy [4]. These figures are estimates and actual prices will fluctuate based on specific manufacturers, dosage strengths, and geographic markets.
• Factors Influencing Generic Pricing:
  • Number of Generic Entrants: A greater number of manufacturers typically leads to more aggressive pricing.
  • Negotiated Rebates and Discounts: Pharmacy Benefit Managers (PBMs) and insurance companies negotiate rebates that impact net prices.
  • Dosage Strengths: Different dosage strengths will have corresponding pricing variations.
  • Market Competition: The competitive intensity among generic manufacturers will dictate price levels.

What is the Outlook for Latuda's Market Beyond Generic Entry?

The market for lurasidone hydrochloride will transition from a branded, patent-protected product to a genericized commodity. The originator brand will see a substantial decline in sales and market share.

• Dominance of Generics: Generic lurasidone will become the primary form of the drug prescribed and dispensed. The market will be characterized by price-driven competition among generic manufacturers.
• Sumitomo Pharma's Strategy: Sumitomo Pharma, the originator, will likely focus on managing the decline of Latuda sales and shifting resources to its pipeline or other commercialized products. They may also pursue authorized generics or partnerships to maintain some presence.
• Continued Therapeutic Relevance: Lurasidone's established efficacy in schizophrenia and bipolar depression means that the drug itself will remain a relevant treatment option. The therapeutic need for lurasidone will persist, ensuring a stable demand for its generic forms.
• Potential for Extended-Release Formulations: While not currently a major focus for generic entry for Latuda, development of generic extended-release (ER) or long-acting injectable (LAI) formulations of antipsychotics can represent a later wave of generic competition and market segmentation.
• Global Market Dynamics: The timeline for patent expiry and generic entry can vary by country. While the U.S. market has seen recent genericization, other regions may follow different timelines based on local patent laws and regulatory approvals.

The long-term market for lurasidone will be defined by its accessibility and affordability as a generic medication, continuing to serve patients with schizophrenia and bipolar depression.

---

Key Takeaways

• The global market for lurasidone hydrochloride was valued at approximately USD 3.4 billion in 2023 and is projected to grow at a CAGR of 5.8% through 2030.
• Key U.S. patents for Latuda have expired, leading to the entry of generic lurasidone hydrochloride products in early 2023.
• Generic competition is expected to result in a significant price reduction for lurasidone, with estimated price decreases of 70-85% compared to the branded product.
• The market share for branded Latuda is projected to decline substantially, with generic versions becoming the dominant treatment option.
• Lurasidone will remain a therapeutically relevant option for schizophrenia and bipolar depression, with demand continuing through its generic forms.

---

Frequently Asked Questions

1. When did generic lurasidone first become available in the United States? Generic lurasidone hydrochloride began entering the U.S. market in early 2023.

2. What are the primary indications for which lurasidone is prescribed? Lurasidone is prescribed for the treatment of schizophrenia and depressive episodes associated with bipolar I disorder.

3. Will the availability of generic lurasidone impact the overall growth of the antipsychotic market? The entry of generic lurasidone will shift market share and pricing within the antipsychotic segment but is unlikely to significantly alter the overall market growth trajectory, which is driven by broader factors like disease prevalence and treatment access.

4. What is the expected impact of generic lurasidone on healthcare costs? The introduction of affordable generic lurasidone is expected to substantially reduce treatment costs for patients and healthcare systems.

5. Are there any long-acting injectable (LAI) formulations of lurasidone available or expected? As of current market analysis, there are no widely available generic or branded long-acting injectable formulations of lurasidone. The primary generic competition is for the oral tablet formulation.

---

Citations

[1] World Health Organization. (n.d.). Schizophrenia. Retrieved from https://www.who.int/news-room/fact-sheets/detail/schizophrenia [2] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/drugsatfda/index.cfm [3] Sumitomo Pharma Co., Ltd. (2023). Financial Results for the Fiscal Year Ended March 31, 2023. [4] Healthcare economics and market analysis reports (proprietary data and industry trend analysis).